Prospective study of insulin-like growth factor-I, insulinlike growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease

International Journal of Molecular Epidemiology and Genetics

Volumn 2, Issue 3, 2011, Pages 261-285

  Ricketts, Sally L ^a   Rensing, Katrijn L ^b   Holly, Jeff M ^c   Chen, Li ^d   Young, Elizabeth H ^a,e   Luben, Robert ^a   Ashford, Sofie ^a   Song, Kijoung ^f   Yuan, Xin ^f   Dehghan, Abbas ^g   Wright, Benjamin J ^h   Waterworth, Dawn M ^f   Mooser, Vincent ^f   Waeber, Gérard ⁱ   Vollenweider, Peter ⁱ   Epstein, Stephen E ^j   Burnett, Mary S ^j   Devaney, Joseph M ^j   Hakonarson, Hakon H ^k   Rader, Daniel J ^l,m   Reilly, Muredach P ^l,m   Danesh, John ^a   Thompson, Simon G ⁿ   Dunning, Alison M ^a   van Duijn, Cornelia M ^g   Samani, Nilesh J ^o   McPherson, Ruth ^d   Wareham, Nicholas J ^p   Khaw, Kay Tee ^a   Boekholdt, S Matthijs ^b   Sandhu, Manjinder S ^a,e,p   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f GLAXOSMITHKLINE   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j WASHINGTON HOSPITAL CENTER   (United States)

^k CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^o UNIVERSITY OF LEICESTER   (United Kingdom)

^p ADDENBROOKE S HOSPITAL   (United Kingdom)

more..

Author keywords

Epidemiology; Genetics of cardiovascular disease; IGF1; IGFBP3; Risk factors

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 80052583050     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140: 19-24.
2. Holly J and Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006; 83: 154-160.
3. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, and Ross J, Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-627.
4. Kotlyar AA, Vered Z, Goldberg I, Chouraqui P, Nas D, Fridman E, Chen-Levy Z, Fytlovich S, Sangiorgi G, Spagnoli LG, Orlandi A, Savion N, Eldar M, and Scheinowitz M. Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine. Heart 2001; 86: 693-700.
5. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, and Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997; 100: 1991-1999.
6. Ren J, Samson WK, and Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999; 31: 2049-2061.
7. Donath MY, Sutsch G, Yan XW, Piva B, Brunner HP, Glatz Y, Zapf J, Follath F, Froesch ER, and Kiowski W. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 1998; 83: 3177-3183.
8. Janssen JA, Stolk RP, Pols HA, Grobbee DE, and Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998; 18: 277-282.
9. Janssen JA and Lamberts SW. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002; 146: 467-477.
10. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, and Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003; 157: 25-31.
11. Schneider HJ, Klotsche J, Saller B, Bohler S, Sievers C, Pittrow D, Ruf G, Marz W, Erwa W, Zeiher AM, Silber S, Lehnert H, Wittchen HU, and Stalla GK. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. Eur J Endocrinol 2008; 158: 153-161.
12. Martin RM, Gunnell D, Whitley E, Nicolaides A, Griffin M, Georgiou N, Davey SG, Ebrahim S, and Holly JM. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab 2008; 93: 1331-1338.
13. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, and Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 2009; 160: 25-31.
14. Juul A, Scheike T, Davidsen M, Gyllenborg J, and Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 939-944.
15. Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, and Psaty BM. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 2007; 92: 1319-1325.
16. Laughlin GA, Barrett-Connor E, Criqui MH, and Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004; 89: 114-120.
17. Lawlor DA, Ebrahim S, Smith GD, Cherry L, Watt P, and Sattar N. The association of insulin-likegrowth factor 1 (IGF-1) with incident coronary heart disease in women: Findings from the prospective British Women's Heart and Health Study. Atherosclerosis 2008; 201: 198-204.
18. Page JH, Ma J, Pollak M, Manson JE, and Hankinson SE. Plasma insulinlike growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. Clin Chem 2008; 54: 1682-1688.
19. Saydah S, Graubard B, Ballard-Barbash R, and Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol 2007; 166: 518-526.
20. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, and Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003; 139: 642-648.
21. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, and Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999; 80 Suppl 1: 95-103.
22. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, Ripatti S, Aulchenko YS, Zhang W, Yuan X, Lim N, Luan J, Ashford S, Wheeler E, Young EH, Hadley D, Thompson JR, Braund PS, Johnson T, Struchalin M, Surakka I, Luben R, Khaw KT, Rodwell SA, Loos RJ, Boekholdt SM, Inouye M, Deloukas P, Elliott P, Schlessinger D, Sanna S, Scuteri A, Jackson A, Mohlke KL, Tuomilehto J, Roberts R, Stewart A, Kesäniemi YA, Mahley RW, Grundy SM; Wellcome Trust Case Control Consortium, McArdle W, Cardon L, Waeber G, Vollenweider P, Chambers JC, Boehnke M, Abecasis GR, Salomaa V, Järvelin MR, Ruokonen A, Barroso I, Epstein SE, Hakonarson HH, Rader DJ, Reilly MP, Witteman JC, Hall AS, Samani NJ, Strachan DP, Barter P, van Duijn CM, Kooner JS, Peltonen L, Wareham NJ, McPherson R, Mooser V, Sandhu MS. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 2010; 30: 2264-2276.
23. Stewart AF, Dandona S, Chen L, Assogba O, Belanger M, Ewart G, LaRose R, Doelle H, Williams K, Wells GA, McPherson R, and Roberts R. Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol 2009; 53: 1471-1472.
24. Dandona S, Chen L, Fan M, Alam MA, Assogba O, Belanger M, Williams K, Wells GA, Tang WH, Ellis SG, Hazen SL, McPherson R, Roberts R, and Stewart AF. The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Hum Genet 2010; 127: 101-105.
25. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, and Schunkert H. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443-453.
26. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678.
27. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, and Stefansson K. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007; 316: 1491-1493.
28. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Ardissino D, Merlini PA, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Fetiveau R, Marziliano N, Casari G, Galli M, Ribichini F, Rossi M, Bernardi F, Zonzin P, Piazza A, Mannucci PM, Schwartz SM, Siscovick DS, Yee J, Friedlander Y, Elosua R, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Kathiresan S, Meigs JB, Williams G, Nathan DM, Mac-Rae CA, O'Donnell CJ, Salomaa V, Havulinna AS, Peltonen L, Melander O, Berglund G, Voight BF, Kathiresan S, Hirschhorn JN, Asselta R, Duga S, Spreafico M, Musunuru K, Daly MJ, Purcell S, Voight BF, Purcell S, Nemesh J, Korn JM, McCarroll SA, Schwartz SM, Yee J, Kathiresan S, Lucas G, Subirana I, Elosua R, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burtt N, Gabriel SB, Samani NJ, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall AS, Schunkert H, Erdmann J, Linsel-Nitschke P, Lieb W, Ziegler A, Konig I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Schunkert H, Samani NJ, Erdmann J, Ouwehand W, Hengstenberg C, Deloukas P, Scholz M, Cam bien F, Reilly MP, Li M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein SE, Rader DJ, Scheffold T, Berger K, Stoll M, Huge A, Girelli D, Martinelli N, Olivieri O, Corrocher R, Morgan T, Spertus JA, McKeown P, Patterson CC, Schunkert H, Erdmann E, Linsel-Nitschke P, Lieb W, Ziegler A, Konig IR, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Holm H, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Engert JC, Do R, Xie C, Anand S, Kathiresan S, Ardissino D, Mannucci PM, Siscovick D, O'Donnell CJ, Samani NJ, Melander O, Elosua R, Peltonen L, Salomaa V, Schwartz SM, and Altshuler D. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334-341.
29. Marques-Vidal P, Pecoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, and Vollenweider P. Prevalence and characteristics of vitamin or dietary supplement users in Lausanne, Switzerland: the CoLaus study. Eur J Clin Nutr 2009; 63: 273-281.
30. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, Song K, Yuan X, Johnson T, Ashford S, Inouye M, Luben R, Sims M, Hadley D, McArdle W, Barter P, Kesaniemi YA, Mahley RW, McPherson R, Grundy SM, Bingham SA, Khaw KT, Loos RJ, Waeber G, Barroso I, Strachan DP, Deloukas P, Vollenweider P, Wareham NJ, and Mooser V. LDLcholesterol concentrations: a genome-wide association study. Lancet 2008; 371: 483-491.
31. Stirnadel H, Lin X, Ling H, Song K, Barter P, Kesaniemi YA, Mahley R, McPherson R, Waeber G, Bersot T, Cohen J, Grundy S, Mitchell B, Mooser V, and Waterworth D. Genetic and phenotypic architecture of metabolic syndromeassociated components in dyslipidemic and normolipidemic subjects: the GEMS Study. Atherosclerosis 2008; 197: 868-876.
32. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesaniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Sharma SS, Nolan V, Middleton LT, Sundseth SS, Farrer LA, Mooser V, and Grundy SM. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 2005; 95: 194-198.
33. Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, Tiemeier H, Uitterlinden AG, Vingerling JR, and Witteman JC. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007; 22: 819-829.
34. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus EJ, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K, Isaacs A, Sijbrands EJ, Uitterlinden AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Doring A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM, and Peltonen L. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41: 47-55.
35. Barrett JC, Fry B, Maller J, and Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
36. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, and Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37: 1217-1223.
37. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, and Dunning AM. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006; 15: 1-10.
38. Rodriguez S, Gaunt TR, and Day IN. Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Hum Genet 2007; 122: 1-21.
39. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, and Pike MC. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003; 55: 27-36.
40. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, and Khaw KT. Creactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006; 187: 415-422.
41. Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, and Kittles RA. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 2007; 28: 2154-2159.
42. Kaushal K, Heald AH, Siddals KW, Sandhu MS, Dunger DB, Gibson JM, and Wareham NJ. The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care 2004; 27: 2682-2688.
43. Friedrich N, Haring R, Nauck M, Ludemann J, Rosskopf D, Spilcke-Liss E, Felix SB, Dorr M, Brabant G, Volzke H, and Wallaschofski H. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab 2009; 94: 1732-1739.
44. Sandhu MS, Gibson JM, Heald AH, Dunger DB, and Wareham NJ. Association between insulinlike growth factor-I: insulin-like growth factorbinding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol Biomarkers Prev 2004; 13: 166-170.
45. D'Aloisio AA, Schroeder JC, North KE, Poole C, West SL, Travlos GS, and Baird DD. IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev 2009; 18: 954-966.
46. Diorio C, Brisson J, Berube S, and Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 2008; 17: 880-888.
47. Johansson M, McKay JD, Wiklund F, Rinaldi S, Verheus M, van Gils CH, Hallmans G, Balter K, Adami HO, Gronberg H, Stattin P, and Kaaks R. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metab 2007; 92: 4820-4826.
48. Patel AV, Cheng I, Canzian F, Le ML, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, and Feigelson HS. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 2008; 3:e2578
49. Verheus M, McKay JD, Kaaks R, Canzian F, Biessy C, Johansson M, Grobbee DE, Peeters PH, and van Gils CH. Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density. Breast Cancer Res Treat 2008; 112: 109-122.
50. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Buenode-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, and Kaaks R. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGFI and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006; 94: 299-307.
51. Cheng I, DeLellis HK, Haiman CA, Kolonel LN, Henderson BE, Freedman ML, and Le ML. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 2007; 92: 3660-3666.
52. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, and Pollak M. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001; 86: 1274-1280.
53. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, and Pollak M. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10: 377-384.
54. Frayling TM, Hattersley AT, McCarthy A, Holly J, Mitchell SM, Gloyn AL, Owen K, Davies D, Smith GD, and Ben-Shlomo Y. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 2002; 51: 2313-2316.
55. Morimoto LM, Newcomb PA, White E, Bigler J, and Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 2005; 14: 394-1401.
56. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, and van Duijn CM. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001; 50: 637-642.
57. Yazdanpanah M, Rietveld I, Janssen JA, Njajou OT, Hofman A, Stijnen T, Pols HA, Lamberts SW, Witteman JC, and van Duijn CM. An insulin-like growth factor-I promoter polymorphism is associated with increased mortality in subjects with myocardial infarction in an elderly Caucasian population. Am J Cardiol 2006; 97: 1274-1276.
58. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Magi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JRB, Egan JM, Lajunen T, Grarup N, Sparso T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proenca C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Roccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YDI, Chines P, Clarke R, Coin LJM, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day INM, de Geus EJC, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL, Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PRV, Jorgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martinez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orru M, Pakyz R, Palmer CNA, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AFH, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, sson G, Sijbrands EJG, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvanen AC, Tanaka T, Thorand B, Tichet J, Tonjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemsen G, Witteman JCM, Yarnell JWG, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, Borecki IB, Loos RJF, Meneton P, Magnusson PKE, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Rios M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WHL, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, and Pramstaller PP. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42: 105-116.
59. Palles C, Johnson N, Coupland B, Taylor C, Carvajal J, Holly J, Fentiman IS, Silva IS, Ashworth A, Peto J, and Fletcher O. Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. Hum Mol Genet 2008; 17: 1457-1464.
60. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tj+©nneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand Lc, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, and Ma J. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Molecular Genetics 2010; 19: 3089-3101.